DiaSys Announces Three Year Exclusive Distributor Agreement for Sales of Infectious Disease Diagnostics in Pakistan & Afghanistan.Business Editors/Health/Medical Writers WATERBURY, Conn.--(BUSINESS WIRE)--Sept. 25, 2003 DiaSys Corporation (AMEX AMEX See: American Stock Exchange :DYX DYX Dyslexia ), a global healthcare products company, today announced that it had made an exclusive three-year distributor sales agreement with Pakistan Medical Links, of Peshawar, one of Pakistan's longest-established diagnostics companies. Under the agreement, Pakistan Medical Links will exclusively promote, sell and service DiaSys product lines throughout Pakistan & Afghanistan, including the DiaSys "FE" Series Workstations used to analyze human body fluids for parasites, the DiaSys Parasep system of single-use containers for the collection, filtration and analysis of parasites in human body fluids, and the DiaSys R/S R/S Remote Sensing R/S Rally Sport R/S Respectfully Submit R/S Report of Survey R/S Route Sheet R/S Reentry System R/S Revision Segment R/S Rationalization & Standardization R/S Regulatory or Safety (automotive requirements) 2003 Workstations for urine sediment analysis. Mr. Tariq Mehmood, Chief Executive and owner says, "Pakistan Medical Links was established in 1992 and, with our head offices in Peshawar and sales offices throughout Pakistan & Kabul Afghanistan, we are well positioned to take advantage of the opportunities with DiaSys products. We already have a strong base of products from other principal companies and these additional ones will fill an important gap in Pakistan Medical Links product range. A company such as DiaSys and its products are really a change for our country in the area of diagnostics and we hope that this will open new opportunities for both of us. Diagnostics for infectious diseases infectious diseases: see communicable diseases. have a critical role to play in the healthcare of our countries." John Aspden, Director of Sales & Marketing, DiaSys Europe said: "Healthcare in Pakistan and Afghanistan, with a combined population of nearly 180 million people, is one of the most important sectors identified for investment in this region by many eastern & western countries. With a strong commitment for eradication of some of the largest reasons for mortality in both countries; intestinal & blood-borne infectious diseases, DiaSys is well placed to address these areas with several products in their parasitology Parasitology The scientific study of parasites and of parasitism. Parasitism is a subdivision of symbiosis and is defined as an intimate association between an organism (parasite) and another, larger species of organism (host) upon which the parasite is & infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. rapid-test range. The recently FDA-certified Leishmania Leishmania /Leish·ma·nia/ (lesh-ma´ne-ah) a genus of parasitic protozoa, including several species pathogenic for humans. In some classifications, organisms are placed in four complexes comprising species and subspecies: L. RapydTest for the detection of visceral leishmania, endemic in Pakistan & Afghanistan, will also be important to the success of both our businesses in this region." DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion